Brain cancer vaccine - Advanced BiotherapiesAlternative Names: Antisense TGF-beta-2 gene therapy
Latest Information Update: 01 Jun 2006
At a glance
- Originator Advanced Biotherapies
- Class Antisense DNA; Cancer vaccines; Cell therapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants; Transforming growth factor beta2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glioblastoma